London Stock Exchange welcomes 4basebio UK Societas to AIM

London Stock Exchange welcomes 4basebio UK Societas (“4basebio”, “4bb” or the “Company”) to AIM today. The Cambridge-based Company’s Ordinary Shares were admitted to trading at 8.00am on Wednesday 17th February 2021.  

The Company’s TIDM is 4BB.LON and at the Admission price of 118p, has a market capitalisation of £14.53m. No new equity has been raised.  

On 8 December 2020, the Company was spun-out of 4basebio AG (Heidelberg), which is listed on the Frankfurt Main Market, with that company now re-focusing as an investment and holding company.  

4bb is a life sciences company focused on exploiting its intellectual property in the field of gene therapies and DNA vaccines. Using its proprietary technology, 4bb is developing and supplying next generation therapeutic DNA, as well as non-viral nanoparticles for use in gene therapy delivery.

The Company’s focus is: 

•    developing a highly efficient and scalable manufacturing process for its proprietary synthetic hpDNATM with a view to manufacturing and selling large quantities of pharmaceutical grade DNA;
•    developing gene therapy delivery systems centred on non-viral nanoparticles; and
•    identifying a number of indications, where the combination of the company’s DNA and non-viral delivery system technology can be combined to progress potential gene therapies through pre-clinical development.

The immediate objectives of 4bb are to validate and scale its DNA synthesis process and advance its collaborations to facilitate the functional validation of its DNA based products and gene delivery solutions.

The Company is well-funded to achieve its development objectives, with approximate cash resources of £14.4million upon AIM admission.

Dr Heikki Lanckriet, Company CEO, commented: “We are delighted to be admitted to AIM today. As a Cambridge, UK based company with significant ambitions, we believe AIM is the ideal market to support our future growth.”

“We would like to thank London Stock Exchange for its warm welcome, and extend our thanks also to our staff, advisors and shareholders who have supported our ongoing development. We look forward to their continued support as we commence the next phase of our growth strategy.”

Quick facts

Market: AIM
Instrument market cap (£m)
Listing/Admission to trading
17 Feb 2021
Looking for new and recent issues?

More recent

London Stock Exchange welcomes Spinnaker Acquisitions Plc to the Main Market

Spinnaker Acquisitions Plc (“SPAQ”) is a newly established purpose-built cash shell aiming to support businesses and projects in the areas of Sustainability and Energy Transition. With interest in the green economy as keen as it is currently, the objective is to find a business valued at £5–30M with strong profit potential and likely market appetite. 

SPAQ is a company co-founded

Learn more
London Stock Exchange welcomes BIG TECHNOLOGIES PLC to AIM

Big Technologies PLC, the UK-based, remote people monitoring technology company, has today taken the next step in its long-term growth strategy as it is admitted to AIM of London Stock Exchange. It is now trading on AIM, having raised gross proceeds in excess of £200 million, with ticker BIG. At the placing price of 200p per share, Big Technologies PLC has a market capitalisation of £577 millio

Learn more
London Stock Exchange welcomes Northcoders Group PLC to AIM

London Stock Exchange today welcomes Northcoders Group plc (‘Northcoders’), an independent provider of training programmes for software coding, to AIM under the stock market ticker CODE. The Admission price was 180p, resulting in a market capitalisation of £12.5milion. The Group joins the market to allow it to access the capital it needs to facilitate its growth strategy, particularly enabling

Learn more
London Stock Exchange welcomes Bridgepoint Group plc to the Premium Segment of the Main Market

Today, Bridgepoint, the UK headquartered, leading mid-market private asset firm in the world, has reached an important milestone as it begins trading on the Main Market of the London Stock Exchange. Bridgepoint priced its initial public offering at 350 pence per share, leading to a total market capitalisation at the commencement of conditional dealings at approximately £2,881 million, which equ

Learn more